Literature DB >> 29018892

Novel treatment opportunities for sulfur mustard-related cancers: genetic and epigenetic perspectives.

Soheila Rahmani1, Mohammad Abdollahi2,3.   

Abstract

Sulfur mustard (SM), also known as mustard gas, is a chemical weapon which by now has been used in many wars. The most concerning SM toxic effect is probable carcinogenicity. In this study, the genetic and epigenetic mechanisms of SM carcinogenicity, by focusing on treatment of SM-associated malignancies, particularly gene therapeutics, cancer vaccines, and epigenetic medications, have been criticized. The required data were collected through an organized search on valid scientific databases. For SM carcinogenicity due to acute or chronic exposure, the entire original and review articles were evaluated. In addition, studies on the therapeutic effects of available genetic and epigenetic medications were included. Currently, four gene therapeutics, two cancer vaccines with genetic bases, and seven epigenetic medications are available for cancer treatment. Genetic and epigenetic cancer treatments including Gendicine, Imlygic, Provenge, Cimavax-EGF, Azacitidine, Vorinostat, Romidepsin, and Belinostat will yield outstanding benefits for SM-exposed patients who suffer from cancer.

Entities:  

Keywords:  Cancer; Cancer vaccine; Epigenetic therapy; Gene therapy; Sulfur mustard

Mesh:

Substances:

Year:  2017        PMID: 29018892     DOI: 10.1007/s00204-017-2086-7

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  2 in total

Review 1.  Toxicology of Blister Agents: Is Melatonin a Potential Therapeutic Option?

Authors:  Alejandro Romero; Eva Ramos; Francisco López-Muñoz; Cristóbal De Los Ríos; Javier Egea; Emilio Gil-Martín; René Pita; Juan J Torrado; Dolores R Serrano; Antonio Juberias
Journal:  Diseases       Date:  2021-04-10

2.  Integrative analysis of DNA methylation-driven genes for the prognosis of lung squamous cell carcinoma using MethylMix.

Authors:  Rui Li; Yun-Hong Yin; Jia Jin; Xiao Liu; Meng-Yu Zhang; Yi-E Yang; Yi-Qing Qu
Journal:  Int J Med Sci       Date:  2020-03-05       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.